343 related articles for article (PubMed ID: 22972909)
1. Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.
Salvatorelli E; De Tursi M; Menna P; Carella C; Massari R; Colasante A; Iacobelli S; Minotti G
Drug Metab Dispos; 2012 Dec; 40(12):2365-73. PubMed ID: 22972909
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.
Harrison LE; Bryan M; Pliner L; Saunders T
Ann Surg Oncol; 2008 May; 15(5):1407-13. PubMed ID: 18157576
[TBL] [Abstract][Full Text] [Related]
3. Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.
Massari R; Barone M; Basilico R; Carella C; Colasante A; De Tursi M; Filippone A; Guetti L; Mani A
Minerva Chir; 2014 Feb; 69(1):17-26. PubMed ID: 24675243
[TBL] [Abstract][Full Text] [Related]
4. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
5. Peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian peritoneal carcinomatosis: an argued role.
Di Giorgio A; Cardi M; Sammartino P
Gynecol Oncol; 2010 Apr; 117(1):146-7. PubMed ID: 20096922
[No Abstract] [Full Text] [Related]
6. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.
de Lima Vazquez V; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Aug; 52(2):108-12. PubMed ID: 12759776
[TBL] [Abstract][Full Text] [Related]
7. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer.
Cascales Campos PA; Gil Martínez J; Galindo Fernández PJ; Gil Gómez E; Martínez Frutos IM; Parrilla Paricio P
Eur J Surg Oncol; 2011 Jun; 37(6):543-8. PubMed ID: 21489742
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.
Ansaloni L; Coccolini F; Morosi L; Ballerini A; Ceresoli M; Grosso G; Bertoli P; Busci LM; Lotti M; Cambria F; Pisano M; Rossetti D; Frigerio L; D'Incalci M; Zucchetti M
Br J Cancer; 2015 Jan; 112(2):306-12. PubMed ID: 25461804
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis.
Cattel L; De Simone M; Passera R; Verlengo MC; Delprino L
Anticancer Res; 2004; 24(3b):2041-5. PubMed ID: 15274398
[TBL] [Abstract][Full Text] [Related]
10. [Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer].
Ferron G; Martinez A; Mery E; Querleu D; Thomas F; Chatelut E; Gladieff L
Bull Cancer; 2009 Dec; 96(12):1243-52. PubMed ID: 19948452
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
Di Giorgio A; Naticchioni E; Biacchi D; Sibio S; Accarpio F; Rocco M; Tarquini S; Di Seri M; Ciardi A; Montruccoli D; Sammartino P
Cancer; 2008 Jul; 113(2):315-25. PubMed ID: 18473354
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients with peritoneal metastases.
Sugarbaker PH; Stuart OA
Eur J Surg Oncol; 2021 Jan; 47(1):108-114. PubMed ID: 30954354
[TBL] [Abstract][Full Text] [Related]
13. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
Roviello F; Pinto E; Corso G; Pedrazzani C; Caruso S; Filippeschi M; Petrioli R; Marsili S; Mazzei MA; Marrelli D
J Surg Oncol; 2010 Nov; 102(6):663-70. PubMed ID: 20721959
[TBL] [Abstract][Full Text] [Related]
14. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.
Rossi CR; Foletto M; Mocellin S; Pilati P; De SM; Deraco M; Cavaliere F; Palatini P; Guasti F; Scalerta R; Lise M
Cancer; 2002 Jan; 94(2):492-9. PubMed ID: 11900234
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis.
Delotte J; Desantis M; Frigenza M; Quaranta D; Bongain A; Benchimol D; Bereder JM
Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():111-4. PubMed ID: 24300558
[TBL] [Abstract][Full Text] [Related]
17. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis.
Sugarbaker PH; Van der Speeten K; Anthony Stuart O; Chang D
Eur J Surg Oncol; 2011 Aug; 37(8):719-26. PubMed ID: 21621952
[TBL] [Abstract][Full Text] [Related]
18. [Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].
Vaira M; Scuderi S; Costamagna D; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Chir; 2002 Oct; 57(5):597-605. PubMed ID: 12370661
[TBL] [Abstract][Full Text] [Related]
19. [Intraoperative intraperitoneal chemoperfusion treatment with cisplatin and dioxadet on a model of peritoneal carcinomatosis in ovarian cancer: safety and efficacy evaluation].
Bespalov VG; Kireeva GS; Belyaeva OA; Senchik KY; Stukov AN; Gafton GI; Soloviev LA; Vasilchenko MV; Guseinov KD; Alexeev VV; Belyaev AM
Vopr Onkol; 2015; 61(4):647-52. PubMed ID: 26571838
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
